Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Biotechnology

Healthcare
$398.08 -0.27%

-$1.33 today

Market cap
$9.25B
Beta
-1.06
P/E (TTM)
-46.9
EPS (TTM)
-$10.66
52W Low $276.67High $615.00

Volume 0.64M

Average 0.31M

MDGL Income Before Tax

Profit after all operating and non-operating items but before income tax.

Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$57.94M, compared with -$42.28M a year earlier. Trailing-twelve-month income before tax was -$325.1M.

Context

  • Income before tax amounted to 30.1% of revenue in FY2025, down 228.6 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$57.94M or moves back toward the trailing-twelve-month quarterly average of -$81.27M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$57.94M+38.6% QoQ
Last fiscal yearDec 2025
-$288.28M+38.1% YoY
LTMJun 2026
-$325.1M-15.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-37.0%——
1 year+38.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(288.28M) USD
Year-over-year change
+38.1%

Income Before Tax vs competitors

How MDGL compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.3% is the 3rd highest of 7, against a peer median of -71.4%.
  • Income before tax amounts to 25.3% of revenue for MDGL, versus a peer median of 5640.2%.
MDGL Competitors
Income Before Tax for MDGL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SGMTSagimet Biosciences Inc.LTM Mar 2026-$43.51M USD+23.8%——
ALTAltimmune, Inc.LTM Mar 2026-$91.08M USD-0.2%—253002.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$122.54M USD-330.7%—612.7%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026-$259.5M USD-56.6%—3644.2%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026-$325.1M USD-15.3%—25.3%
IVAInventiva S.A.FY2025-€342.33M EUR-86.1%—7636.1%
VKTXViking Therapeutics, Inc.LTM Jun 2026-$534.8M USD-211.7%——
Peer median (excluding MDGL) —-71.4%—5640.2%

Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000180.13M958.4M
Cost of Revenue0006.23M56.15M
Gross Profit000173.9M902.26M
Gross Margin———96.5%94.1%
Research & Development205.16M245.44M272.35M236.72M388.53M
Selling, General & Admin37.32M48.13M108.15M435.06M813.83M
Operating Expenses242.48M293.57M380.5M671.78M1.2B
Depreciation & Amortization405K467K527K1.1M1.51M
EBITDA(241.44M)(290.92M)(360.39M)(450.13M)(264.47M)
EBITDA Margin———-249.9%-27.6%
Operating Income(242.48M)(293.57M)(380.5M)(497.88M)(300.1M)
Operating Margin———-276.4%-31.3%
Interest Income363K2.19M19.58M46.65M37.36M
Interest Expense03.96M12.71M14.67M22.31M
Other Income / Expenses636K(1.78M)6.87M31.98M11.81M
Income Before Tax(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Pre-Tax Margin———-258.6%-30.1%
Income Tax Expense00000
Net Income(241.85M)(295.35M)(373.63M)(465.89M)(288.28M)
Net Margin———-258.6%-30.1%
EPS (Basic)(14.63)(17.23)(19.99)(21.90)(12.85)
EPS (Diluted)(14.63)(17.23)(19.99)(21.90)(12.85)
Weighted Avg Shares16.54M17.14M18.69M21.27M22.43M
Weighted Avg Shares (Diluted)16.54M17.14M18.69M21.27M22.43M

Madrigal Pharmaceuticals, Inc.

NASDAQ:MDGL

Intrinsic Alpha fair value

Locked

Current Price

$398.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.